Everstone Group to invest up to $50 mln in Slayback Pharma

The Everstone Group has agreed to invest up to $50 million in Series B funding in Slayback Pharma.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this